CHMP Favors Approval of Hulio, Biosimilar to Humira, to Treat IBD Patients in EU

CHMP Favors Approval of Hulio, Biosimilar to Humira, to Treat IBD Patients in EU
Hulio, a biosimilar to Humira (adalimumab), has been given a favorable opinion by the Committee for Medicinal Products for Human Use (CHMP) to treat a number of inflammatory diseases in the EU — including Crohn's disease and ulcerative colitis, the product's manufacturers,  Mylan and Fujifilm Kyowa Kirin Biologics, announced in a press r
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *